BCD 085

Drug Profile

BCD 085

Alternative Names: BCD-085

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Biocad
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 17 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ankylosing spondylitis; Plaque psoriasis

Most Recent Events

  • 08 Jun 2016 Pharmacokinetics and adverse event data from a phase I trial in Healthy volunteers presented at the 17th Annual Congress of the European League Against Rheumatism (ELAR-2016)
  • 01 Jun 2016 Phase-II clinical trials in Plaque psoriasis in Russia (SC) (9205013; NCT02762994)
  • 01 Oct 2015 Biocad completes a phase I trial in Autoimmune disorders (In volunteers) in Russia (SC) (NCT02380287)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top